Stockreport

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Jasper Therapeutics, Inc. - Class A  (JSPR) 
PDF REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on developmen [Read more]